Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BYPharmaceutics

Artificial Intelligence-Driven Nanomedicine: From Drug Formulation and Nanocarrier Design to Clinical Translation

  1. 1Department of Pharmaceutical Sciences, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh 11426, Saudi Arabia

Abstract

The integration of artificial intelligence (AI) and machine learning (ML) is fundamentally transforming pharmaceutical sciences, shifting drug formulation and nanocarrier design from traditional empirical approaches toward predictive, data-driven methodologies. By enabling the analysis of large, complex datasets, AI technologies are accelerating decision-making, improving formulation efficiency, and supporting the development of more effective therapeutic systems. Despite these advances, the successful clinical translation of advanced nanomedicines, including polymeric nanoparticles and mRNA-lipid nanoparticle platforms, remains limited by challenges such as biological barriers, highly sensitive formulation parameters, scalability issues, and the limited interpretability of many computational models. This review provides a comprehensive overview of AI applications throughout the pharmaceutical development lifecycle. It explores how classical machine learning algorithms and deep learning architectures optimize conventional dosage forms, enhance formulation development, and enable the rational design of targeted nanocarriers. Particular emphasis is placed on predicting critical quality attributes, encapsulation efficiency, physicochemical properties, drug-release behavior, therapeutic efficacy, and early-stage nanotoxicity. Furthermore, we critically assess the regulatory considerations, manufacturing constraints, data quality issues, and tumor microenvironment heterogeneity that continue to impede bench-to-clinic translation. Ultimately, overcoming these challenges requires moving beyond isolated algorithmic optimization toward an integrated framework that combines computational intelligence, robust experimental validation, and continuous clinical feedback. Such a synergistic approach is expected to drive the next generation of precision nanomedicine and facilitate the safe and effective translation of AI-enabled pharmaceutical innovations into clinical practice.

Related

  1. Artificial Intelligence-Enabled Nanomedicine in Precision Oncology: Diagnosis, Targeted Therapy, and Clinical Translation.
    Ruba Altahla, Yongping Wang, Mahdi Morshedi Yekta +7
    International journal of nanomedicinePeer-reviewedCC BY-NCFull textMaterials & polymersEurope PMCPMC
  2. Artificial intelligence and machine learning-guided bio-orthogonal engineering of smart soft polymeric nanocarriers for precision drug delivery and translational nanomedicine
    Suman Basak
    Frontiers in Soft MatterPeer-reviewedCC BYFull text9 citedMaterials & polymersOpenAlex
  3. An Integrated Artificial Intelligence Framework for Nanomedicine Engineering
    Meichen Dong, Qin Luo, Xinyi Ding +8
    Advanced SciencePeer-reviewedCC BY 4.0Full textMaterials & polymersPMC
  4. Nanocarrier-Mediated Immunotherapy for Gynecological Malignancies: Mechanisms, Clinical Translation, and Emerging Nucleic Acid-Based Strategies.
    Miaomiao Fu, Ruimin Zhao, Yiyan Cao +3
    International journal of nanomedicinePeer-reviewedCC BY-NCFull textMaterials & polymersEurope PMCPMC
  5. Artificial Intelligence in Nanopharmaceutical Development: From Predictive Design to Clinical Translation
    Renato Sonchini Gonçalves
    PharmaceuticsPeer-reviewedCC BYFull text11 citedMaterials & polymersOpenAlex
BibTeX
@article{alsaqabi2026artificial,
  title = {{Artificial Intelligence-Driven Nanomedicine: From Drug Formulation and Nanocarrier Design to Clinical Translation}},
  author = {Abdulrahman A. Alsaqabi and Abdulaziz A. Almoutairi and Faisal Alnehari and Abdulaziz N. Alanazi and Rema Aldugiem and Yara Alsaeed and Sarah M Alotaibi},
  journal = {Pharmaceutics},
  year = {2026},
  month = jul,
  doi = {10.3390/pharmaceutics18070845},
  url = {https://doi.org/10.3390/pharmaceutics18070845},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Artificial Intelligence-Driven Nanomedicine: From Drug Formulation and Nanocarrier Design to Clinical Translation
AU  - Abdulrahman A. Alsaqabi
AU  - Abdulaziz A. Almoutairi
AU  - Faisal Alnehari
AU  - Abdulaziz N. Alanazi
AU  - Rema Aldugiem
AU  - Yara Alsaeed
AU  - Sarah M Alotaibi
PY  - 2026
DA  - 2026/07/11
JO  - Pharmaceutics
DO  - 10.3390/pharmaceutics18070845
UR  - https://doi.org/10.3390/pharmaceutics18070845
AB  - The integration of artificial intelligence (AI) and machine learning (ML) is fundamentally transforming pharmaceutical sciences, shifting drug formulation and nanocarrier design from traditional empirical approaches toward predictive, data-driven methodologies. By enabling the analysis of large, complex datasets, AI technologies are accelerating decision-making, improving formulation efficiency, and supporting the development of more effective therapeutic systems. Despite these advances, the successful clinical translation of advanced nanomedicines, including polymeric nanoparticles and mRNA-lipid nanoparticle platforms, remains limited by challenges such as biological barriers, highly sensitive formulation parameters, scalability issues, and the limited interpretability of many computational models. This review provides a comprehensive overview of AI applications throughout the pharmaceutical development lifecycle. It explores how classical machine learning algorithms and deep learning architectures optimize conventional dosage forms, enhance formulation development, and enable the rational design of targeted nanocarriers. Particular emphasis is placed on predicting critical quality attributes, encapsulation efficiency, physicochemical properties, drug-release behavior, therapeutic efficacy, and early-stage nanotoxicity. Furthermore, we critically assess the regulatory considerations, manufacturing constraints, data quality issues, and tumor microenvironment heterogeneity that continue to impede bench-to-clinic translation. Ultimately, overcoming these challenges requires moving beyond isolated algorithmic optimization toward an integrated framework that combines computational intelligence, robust experimental validation, and continuous clinical feedback. Such a synergistic approach is expected to drive the next generation of precision nanomedicine and facilitate the safe and effective translation of AI-enabled pharmaceutical innovations into clinical practice.
SN  - 1999-4923
ER  -